Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIKALO-2: LY4064809 with CDK4/6 inhibitor and endocrine therapy in HR+, HER2- advanced breast cancer with PIK3CA mutation
jRCT2031260363Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of tersolisib in breast cancer (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Overall Response Rate (ORR) in Part 1 and Progression-Free Survival (PFS) in Part 2. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
tersolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031260363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260363.